Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025386 | 0.88 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2TP53ALOX5 | |
| SCHEMBL4026213 | 0.79 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2TP53LMNA | |
| SCHEMBL4026207 | 0.79 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2TP53LMNA | |
| SCHEMBL4029820 | 0.77 | L3MBTL1 (0.57) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL9472171 | 0.77 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2TP53ALOX5 | |
| SCHEMBL2247920 | 0.76 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53MEN1 | |
| SCHEMBL4512157 | 0.76 | KDM4E (0.61) | RAB9ANPC1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL2247503 | 0.75 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2TP53LMNA | |
| SCHEMBL14451614 | 0.74 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2TP53MEN1 | |
| SCHEMBL2245364 | 0.74 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | claimed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | claimed |
| EP-1569916-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD. (IN) | 2005-09-07 | — | — | EP | claimed |
| WO-2004046119-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2004-06-03 | — | — | WO | claimed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | disclosed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | disclosed |
| EP-1569916-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD. (IN) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004046119-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142277-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | RAB9A 543/4885NPC1 1894/4885SMN1; SMN2 2873/4885 |
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | RAB9A 543/4885NPC1 1894/4885SMN1; SMN2 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.